Biosimilars

Adam M. Brufsky, MD, PhD, professor of medicine, associate chief, Division of Hematology/Oncology, co-director, Comprehensive Breast Cancer Center, associate director, Clinical Investigation, University of Pittsburgh, discusses reducing the cost of care in breast oncology.

Epoetin alfa-epbx (Retacrit), the biosimilar to epoetin alfa (Procrit/Epogen) has been launched in the United States at a significant discount.

Mark D. Pegram, MD, Susy Yuan-Huey Hung Professor, co-director, Stanford’s Molecular Therapeutics Program, director, Breast Cancer Oncology Program, Stanford Women’s Cancer Center, discusses the future impact of biosimilars in oncology.

Nancy Nixon, MD, discusses the retrospective study of the evolution of biosimilars in oncology, with a focus on trastuzumab and the path toward the integration of biosimilars into cancer care.

Mohammed J. Rahman, MD, oncologist, University of Pittsburgh Medical Center, discusses his understanding of the role of biosimilars in oncology.

Martina Weise, MD, head of Division Licensing 2, and German CHMP member of the Federal Institute for Drugs and Medical Devices, discusses the future of biosimilars in oncology.

Shannon L. Puhalla, MD, assistant professor of medicine, University of Pittsburgh School of Medicine, medical oncologist and hematologist, UPMC Hillman Cancer Center, discusses the value of biosimilars in oncology.

Adam M. Brufsky, MD, PhD, professor of medicine, associate chief, Division of Hematology/Oncology, co-director, Comprehensive Breast Cancer Center, associate director, Clinical Investigation, University of Pittsburgh, discusses reasons to use biosimilars in oncology.

The FDA has granted an approval to pegfilgrastim-cbqv, a pegfilgrastim biosimilar, for patients with cancer receiving myelosuppressive chemotherapy, according to Coherus BioSciences, Inc, the manufacturer of the agent.

Hope Rugo, MD, professor of medicine, director of the Breast Oncology Clinical Trials Program, UCSF Helen Diller Family Comprehensive Cancer Center, discusses the equivalency that has been demonstrated with biosimilars for trastuzumab (Herceptin).

Kashyap Patel, MD, president of the Carolina Blood and Cancer Center and medical director of the International Oncology Network, discusses the importance of biosimilars in oncology.

Martina Weise, MD, head of Division Licensing 2, and German CHMP member of the Federal Institute for Drugs and Medical Devices, discusses the value of biosimilars in oncology.

Kashyap Patel, MD, discusses biosimilars and other potential cost-controlling measures in cancer care.

Ruth O’Regan, MD, division head, Hematology and Oncology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, discusses biosimilar education in oncology.

Kashyap Patel, MD, president, Carolina Blood and Cancer Center, medical director, International Oncology Network, discusses skepticism associated with biosimilars in oncology.

Martina Weise, MD, discusses the journey of biosimilars as supportive care for patients with cancer, as well as the future of their use as treatment.

Hope Rugo, MD, professor of medicine, director of the Breast Oncology Clinical Trials Program, UCSF Helen Diller Family Comprehensive Cancer Center, discusses a comparative review of trastuzumab (Herceptin) biosimilars.

Martina Weise, MD, head of Division Licensing 2, and German CHMP member of the Federal Institute for Drugs and Medical Devices, discusses challenges with biosimilar acceptance in oncology.

Hope S. Rugo, MD, discusses an analysis of trastuzumab biosimilars in breast cancer.

Ruth O’Regan, MD, discusses the excitement with biosimilars and the potential impact they could have on the US drug market.

Ruth O’Regan, MD, division head, Hematology and Oncology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, discusses the status of biosimilars in oncology.

The FDA’s Oncologic Drugs Advisory Committee voted 16-0 recommending approval of the rituximab biosimilar CT-P10 for 3 non-Hodgkin lymphoma indications.

Pressure to reduce costs associated with biologics is one of the forces driving the rapid expansion of biosimilars, which are biological drugs that are very similar to already approved reference biologics in terms of potency, safety, and efficacy.

Yelena Y. Janjigian, MD, discusses the reality of biosimilars entering the US market and how oncologists should approach discussing these agents with their patients.

Jerald P. Radich, MD, clinical research division, Fred Hutchinson Cancer Research Center, discusses the potential of biosimilars in oncology.